Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by NeoGenomics, Inc.

< Previous 1 2 Next >
NeoGenomics Liquid Biopsy Subsidiary Inivata Announces New Data Demonstrating Clinical Potential of the RaDaR(TM) MRD Test in HR+ HER2- Breast Cancer
From NeoGenomics, Inc.
Via AccessWire
Tickers NEO
NeoGenomics To Participate In Multiple Upcoming Institutional Investor Conferences
From NeoGenomics, Inc.
Via AccessWire
Tickers NEO
NeoGenomics Receives CAP Certification in their Suzhou China Pharma Services Laboratory
From NeoGenomics, Inc.
Via AccessWire
Tickers NEO
NeoGenomics Appoints Lynn Tetrault Interim CEO
From NeoGenomics, Inc.
Via AccessWire
Tickers NEO
NeoGenomics Liquid Biopsy Subsidiary Inivata and Collaborators Present New Data Further Validating the Application of its RaDaR(R) MRD and InVisionFirst(R)-Lung Tests at the 2022 ASCO Annual Meeting
From NeoGenomics, Inc.
Via AccessWire
Tickers NEO
NeoGenomics Announces Leadership Transition Appointing Vishal Sikri as President and Chief Commercial Officer of Inivata Liquid Biopsy Subsidiary
From NeoGenomics, Inc.
Via AccessWire
Tickers NEO
NeoGenomics To Participate in the BofA Securities 2022 Healthcare Conference
From NeoGenomics, Inc.
Via AccessWire
Tickers NEO
NeoGenomics Reports Revenue of $117 Million in the First Quarter
From NeoGenomics, Inc.
Via AccessWire
Exposures COVID-19
Tickers NEO
NeoGenomics Inc. Announces Partnership with Lilly for Lung Cancer Sponsored Testing Program Utilizing the NeoTYPE(R) DNA and RNA Assay
From NeoGenomics, Inc.
Via AccessWire
Tickers NEO
NeoGenomics Announces That Inivata Liquid Biopsy Subsidiary and Collaborators Have Published Clinical Validation Data for RaDaR(TM) Assay MRD Assay at AACR 2022
From NeoGenomics, Inc.
Via AccessWire
Tickers NEO
NeoGenomics, Inc. Expands Its Global Strategic Partnership Initiatives with Biognosys AG on Multiple Next Generation Proteomics Solutions Supporting Biopharma R&D
From NeoGenomics, Inc.
Via AccessWire
Tickers NEO
NeoGenomics Schedules its First Quarter 2022 Earnings Release for April 27, 2022
From NeoGenomics, Inc.
Via AccessWire
Tickers NEO
NeoGenomics Announces CEO Departure and Initiates CEO Search
From NeoGenomics, Inc.
Via AccessWire
Tickers NEO
NeoGenomics Announces That Inivata Liquid Biopsy Subsidiary and Collaborators Have Published Clinical Validation Data for RaDaR(TM) Assay in Non-Small Cell Lung Cancer
From NeoGenomics, Inc.
Via AccessWire
Tickers NEO
NeoGenomics To Participate In Multiple Upcoming Institutional Investor Conferences
From NeoGenomics, Inc.
Via AccessWire
Tickers NEO
NeoGenomics Reports Full Year Revenue of $484 Million and $126 Million for the Fourth Quarter of 2021
From NeoGenomics, Inc.
Via AccessWire
Exposures COVID-19
Tickers NEO
NeoGenomics appoints Dr. Shashi Kulkarni, a World-Renowned Oncology Genomics Expert, and Innovator as Chief Scientific Officer
From NeoGenomics, Inc.
Via AccessWire
Tickers NEO
NeoGenomics Liquid Biopsy Subsidiary Inivata and Collaborators Publish Positive Results from Prospective Clinical Study of RaDaR(TM) in Head and Neck Squamous Cell Carcinoma
From NeoGenomics, Inc.
Via AccessWire
Tickers NEO
NeoGenomics to Participate Virtually in Multiple Upcoming Institutional Investor Conferences
From NeoGenomics, Inc.
Via AccessWire
Tickers NEO
NeoGenomics Schedules its Fourth Quarter and Full Year 2021 Earnings Release for February 23, 2022
From NeoGenomics, Inc.
Via AccessWire
Tickers NEO
NeoGenomics First to Partner with Biomarker Collaborative and Deliver Patient Resources Along with Oncology Testing Results
From NeoGenomics, Inc.
Via AccessWire
Tickers NEO
NeoGenomics Announces RaDaR(TM) Assay Receives CE Mark and is Submitted for US Reimbursement via the MolDX Program
From NeoGenomics, Inc.
Via AccessWire
Tickers NEO
NeoGenomics Appoints David Eberhard MD, PhD as Chief Medical Officer of Inivata Liquid Biopsy Subsidiary
From NeoGenomics, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Product Safety
Tickers NEO
NeoGenomics to Leverage Thermo Fisher Scientific’s Ion Torrent Genexus System in Upcoming Phase 1 Study for Myeloid Cancers
From NeoGenomics, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
Tickers NEO
NeoGenomics To Participate In The Stephens Annual Investment Conference 2021
From NeoGenomics, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
Tickers NEO
NeoGenomics Appoints Dave Daly to Its Board of Directors
From NeoGenomics, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
Tickers NEO
NeoGenomics Reports Revenue of $121 Million in the Third Quarter
From NeoGenomics, Inc.
Via AccessWire
Topics Regulatory Compliance Retirement
Exposures COVID-19 Legal Pension
Tickers NEO
NeoGenomics Announces Leadership Team Transition
From NeoGenomics, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
Tickers NEO
NeoGenomics' Liquid Biopsy Subsidiary Inivata Announces Clinical Collaboration With Princess Margaret Cancer Center for the Use of Its Liquid Biopsy Assays
From NeoGenomics, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Product Safety
Tickers NEO
NeoGenomics Schedules its Third Quarter 2021, Earnings Release for November 4, 2021
From NeoGenomics, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
Tickers NEO
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.